The price of Nektar Therapeutics (NASDAQ:NKTR) shares last traded on Wall Street fell -6.25% to $0.65.
NKTR stock price is now 3.12% away from the 50-day moving average and -58.42% away from the 200-day moving average. The market capitalization of the company currently stands at $121.31M.
With the price target reduced from $1.50 to $1, Jefferies Upgraded its rating from Underperform to Hold for Nektar Therapeutics (NASDAQ: NKTR).
In other news, ROBIN HOWARD W, President & CEO sold 19,998 shares of the company’s stock on Aug 16. The stock was sold for $15,598 at an average price of $0.78. Upon completion of the transaction, the President & CEO now directly owns 919,799 shares in the company, valued at $0.6 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 16, Chief R&D Officer Zalevsky Jonathan sold 9,703 shares of the business’s stock. A total of $7,568 was realized by selling the stock at an average price of $0.78. This leaves the insider owning 283,685 shares of the company worth $0.18 million. Insiders disposed of 222,378 shares of company stock worth roughly $0.14 million over the past 1 year. A total of 1.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NKTR stock. A new stake in Nektar Therapeutics shares was purchased by MONACO ASSET MANAGEMENT SAM during the first quarter worth $5,992,000. SIO CAPITAL MANAGEMENT, LLC invested $4,526,000 in shares of NKTR during the first quarter. In the first quarter, ACUITAS INVESTMENTS, LLC acquired a new stake in Nektar Therapeutics valued at approximately $467,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in NKTR for approximately $245,000. MOLONEY SECURITIES ASSET MANAGEMENT, LLC purchased a new stake in NKTR valued at around $230,000 in the second quarter. In total, there are 258 active investors with 94.80% ownership of the company’s stock.
A candlestick chart of Nektar Therapeutics (NASDAQ: NKTR) showed a price of $0.6914 on Thursday morning. During the past 12 months, Nektar Therapeutics has had a low of $0.51 and a high of $4.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.70, and a quick ratio of 8.30. The fifty day moving average price for NKTR is $0.6288 and a two-hundred day moving average price translates $1.5402 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$0.28 by 0.01. This compares to -$0.85 EPS in the same period last year. The company reported revenue of $20.5 million for the quarter, compared to $21.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -5.03 percent. For the current quarter, analysts expect NKTR to generate $21.48M in revenue.
Nektar Therapeutics(NKTR) Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
